Filing Details
- Accession Number:
- 0001193125-17-252917
- Form Type:
- 13G Filing
- Publication Date:
- 2017-08-09 17:01:58
- Filed By:
- Alnylam Pharmaceuticals, Inc.
- Company:
- Regulus Therapeutics Inc. (NASDAQ:RGLS)
- Filing Date:
- 2017-08-09
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals, Inc | 0 | 0 | 0 | 0 | 0 | 0% |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)*
Regulus Therapeutics Inc.
(Name of Issuer)
COMMON STOCK, $0.001 PAR VALUE PER SHARE
(Title of Class of Securities)
75915K101
(CUSIP Number)
March 24, 2017(1)
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
| * | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| (1) | The reporting person is not required to amend its Schedule 13G filing until after the end of the 2017 calendar year. However, the reporting person has elected to voluntarily amend its Schedule 13G filing at this time to reflect its current beneficial ownership. |
| CUSIP No. 75915K101 |
| 1. | NAMES OF REPORTING PERSONS
Alnylam Pharmaceuticals, Inc. | |||||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐ (b) ☐
| |||||
| 3. | SEC USE ONLY
| |||||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware | |||||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER
0 | ||||
| 6. | SHARED VOTING POWER
0 | |||||
| 7. | SOLE DISPOSITIVE POWER
0 | |||||
| 8. | SHARED DISPOSITIVE POWER
0 | |||||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0 | |||||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
☐ | |||||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
0% | |||||
| 12. | TYPE OF REPORTING PERSON
CO | |||||
Page 2 of 5 Pages
CUSIP No. 75915K101
| Item 1. | Issuer | |||
| (a) | Name of Issuer: | |||
| Regulus Therapeutics Inc. (the Issuer) | ||||
| (b) | Address of Issuers Principal Executive Offices: | |||
| 10614 Science Center Dr. San Diego, CA 92121 | ||||
| Item 2. | Filing Person | |||
| (a) (c) | Name of Person Filing; Address; Citizenship: | |||
| Alnylam Pharmaceuticals, Inc., a Delaware corporation
The address of the principal business office of the reporting person is 300 Third Street, 3rd Floor, Cambridge, MA 02142. | ||||
| (d) | Title of Class of Securities: | |||
| Common stock, $0.001 par value per share | ||||
| (e) | CUSIP Number:
75915K101 | |||
| Item 3. | Description of Person Filing | |||
| Not applicable. | ||||
Page 3 of 5 Pages
CUSIP No. 75915K101
| Item 4. | Ownership. | |||
| (a) and (b) | Amount beneficially owned; percent of class: | |||
| The reporting person directly owns 0 shares, which represents approximately 0% of the outstanding shares of common stock. | ||||
| (c) | Number of shares as to which such person has: | |||
| (i) Sole power to vote or direct the vote
0 shares
(ii) Shared power to vote or to direct the vote
0 shares
(iii) Sole power to dispose or to direct the disposition of
0 shares
(iv) Shared power to dispose or to direct the disposition of
0 shares | ||||
| Item 5. | Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒
Based on 52,932,405 shares of the Issuers common stock outstanding as of February 24, 2017, as disclosed by the Issuer in its Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 3, 2017, the reporting person ceased to be the beneficial owner of more than five percent of the class of securities as of March 24, 2017.
The reporting person is not required to amend its Schedule 13G filing until after the end of the 2017 calendar year. However, the reporting person has elected to voluntarily amend its Schedule 13G filing at this time to reflect its current beneficial ownership. | |
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person.
Not applicable. | |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not applicable. | |
| Item 8. | Identification and Classification of Members of the Group.
Not applicable. | |
| Item 9. | Notice of Dissolution of Group.
Not applicable. | |
| Item 10. | Certification.
Not applicable. | |
Page 4 of 5 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: August 9, 2017
| ALNYLAM PHARMACEUTICALS, INC. | ||
| By: | /s/ Michael P. Mason | |
| Michael P. Mason | ||
| Vice President, Finance and Treasurer | ||
Page 5 of 5 Pages